Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
Coverage (5)
- Zipalertinib plus chemo Phase III success in 1st-line NSCLC The Pharma Letter · 4d ago
- Taiho, Cullinan’s lung cancer drug passes Phase 3 test, lining up Rybrevant contest Endpoints News · 4d ago
- Cullinan, Taiho score Phase III win for zipalertinib combo in first-line NSCLC FirstWord Pharma · 4d ago
- New Taiho, Cullinan data heats up lung cancer drug battle BioPharma Dive · 4d ago
- Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal Fierce Biotech · 4d ago broke it first
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Related trends
Credit card issuer Synchrony partners with OpenAI for ChatGPT shopping
Credit card issuer Synchrony has partnered with OpenAI to bring store cards and shopping offers into ChatGPT.
The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
China's recovery sputters as consumption, output lose steam
China's economic recovery is losing momentum as retail sales, output, and investment slow down.
Alibaba to Sell Videogame Business for at Least $1.5 Billion
Alibaba moves to sell its videogame business to prioritize artificial intelligence and e-commerce.
Big investors hunt for tomorrow's AI winners as capex angst fades
Major investors are shifting focus toward emerging artificial intelligence opportunities as capital expenditure concerns diminish.
Private credit under strain as troubled loans swell
Private credit faces high stress levels and troubled loans, while industry leaders debate systemic risks.